ID 05/26 Issuance of Revised Notice 133 and Notice FHC-N133
Executive Summary
MAS has issued revised Notice 133 and Notice FHC-N133 effective immediately (16 March 2026), introducing **equity counter-cyclical adjustment (CCA)** and new capital treatment rules for **structured products and infrastructure investments**. This represents a material enhancement to Singapore's risk-based capital (RBC 2) framework for all licensed insurers and designated financial holding companies with insurance operations, requiring immediate compliance assessment and system updates.
What Changed
The revised notices introduce several substantive amendments to the valuation and capital framework: Equity Counter-Cyclical Adjustment (CCA) The introduction of equity CCA represents a significant methodological shift in how insurers must calculate capital requirements for equity risk exposure. This mechanism adjusts capital charges based on equity market volatility cycles, requiring insurers to implement dynamic risk modeling rather than static capital calculations. Structured Products Capital Treatment New capital treatment rules for structured products establish specific valuation and risk-charging methodologies. This addresses a previous regulatory gap where structured product classification and capital treatment lacked explicit guidance. Infrastructure Investment Capital Treatment
Suggested Considerations
- *Immediate (within 30 days):
- N133 documents (156 KB PDF available on MAS website)
- *Short-term (30-90 days):
- insurance entity risk charges using the new explicit risk charging approach
- type criteria
- wide consolidated risk calculations reflect updated NIE risk charging
Key Dates
Compliance Impact
Urgency: CRITICAL
Who is Affected
References
AI-generated analysis. May contain errors or omissions — verify with the original MAS source before acting. Full disclaimer.
Summary
Informs insurers on the amendments of Notice 133 and Notice FHC-N133 to include the proposed introduction of equity counter-cyclical adjustment (CCA), and the capital treatment for structured products and infrastructure investments, amongst others.